• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

严重 SARS-CoV-2 感染合并致命性曲霉病:一例报告。

Fatal aspergillosis complicating severe SARS-CoV-2 infection: A case report.

机构信息

Department of internal medicine, University Hospital of Saint-Étienne, Saint-Étienne, France.

Laboratory of infectious agents, Parasitology-Mycology Section, University Hospital of Saint-Étienne, Saint-Étienne, France.

出版信息

J Mycol Med. 2020 Dec;30(4):101039. doi: 10.1016/j.mycmed.2020.101039. Epub 2020 Aug 20.

DOI:10.1016/j.mycmed.2020.101039
PMID:32861584
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7440034/
Abstract

As aspergillosis is a well-known complication of severe influenza, we suggest that SARS-CoV-2 might be a risk factor for invasive aspergillosis (IA). We report the case of an 87 year-old woman, with no history of immune deficit, admitted in our emergency room for severe respiratory distress. Coronavirus disease 2019 (COVID-19) diagnosis was confirmed by a SARS-CoV-2 reverse transcriptase polymerase chain reaction (PCR) on nasal swab. On day 14, pulmonary examination deteriorated with haemoptysis and a major increase of inflammatory response. A computed tomography (CT) scan revealed nodules highly suggestive of IA. Aspergillus antigen was found highly positive in sputum and blood, as was Aspergillusspp PCR on serum. Sputum cultures remained negative for Aspergillus. This patient died rapidly from severe respiratory failure, despite the addition of voriconazole. Considering SARS-CoV-2 acute respiratory distress syndrome (ARDS) as an acquired immunodeficiency, we report here a new case of "probable" IA based on clinical and biological arguments, in accordance with the last consensus definition of invasive fungal disease. On a routine basis, we have detected 30% of aspergillosis carriage (positive culture and antigen in tracheal secretions) in critically ill patients with COVID-19 in our centre. Further studies will have to determine whether sputum or tracheal secretions should be systematically screened for fungal investigations in intensive care unit (ICU) COVID-19 patients to early diagnose and treat aspergillosis.

摘要

由于曲霉菌病是严重流感的一种已知并发症,我们推测严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)可能是侵袭性曲霉菌病(IA)的一个危险因素。我们报告了一例 87 岁女性病例,她没有免疫缺陷病史,因严重呼吸窘迫而被收入我们的急诊室。通过鼻拭子的 SARS-CoV-2 逆转录酶聚合酶链反应(PCR)确诊了 2019 年冠状病毒病(COVID-19)。第 14 天,肺部检查恶化,出现咯血和炎症反应明显增加。计算机断层扫描(CT)显示结节高度提示 IA。痰和血液中的曲霉抗原呈高度阳性,血清中也检测到 Aspergillus spp PCR。痰培养对曲霉仍呈阴性。尽管添加了伏立康唑,该患者仍因严重呼吸衰竭迅速死亡。鉴于 SARS-CoV-2 急性呼吸窘迫综合征(ARDS)是一种获得性免疫缺陷,我们根据临床和生物学依据报告了一例新的“可能”IA 病例,符合侵袭性真菌病的最新共识定义。在我们中心,对 COVID-19 重症患者进行常规检测,发现 30%的患者携带曲霉菌(气管分泌物中培养和抗原阳性)。进一步的研究将不得不确定在 ICU 接受 COVID-19 治疗的患者的痰液或气管分泌物是否应系统筛查真菌以早期诊断和治疗曲霉菌病。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6800/7440034/c853ebd7c262/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6800/7440034/59922fc3e29b/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6800/7440034/c853ebd7c262/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6800/7440034/59922fc3e29b/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6800/7440034/c853ebd7c262/gr2_lrg.jpg

相似文献

1
Fatal aspergillosis complicating severe SARS-CoV-2 infection: A case report.严重 SARS-CoV-2 感染合并致命性曲霉病:一例报告。
J Mycol Med. 2020 Dec;30(4):101039. doi: 10.1016/j.mycmed.2020.101039. Epub 2020 Aug 20.
2
Subacute Aspergillosis "Fungal Balls" Complicating COVID-19.亚急性曲霉病“真菌球”并发新型冠状病毒肺炎
J Investig Med High Impact Case Rep. 2020 Jan-Dec;8:2324709620966475. doi: 10.1177/2324709620966475.
3
Fatal Invasive Aspergillosis and Coronavirus Disease in an Immunocompetent Patient.免疫功能正常患者的侵袭性曲霉病和冠状病毒病致死。
Emerg Infect Dis. 2020 Jul;26(7):1636-1637. doi: 10.3201/eid2607.201603. Epub 2020 Jun 21.
4
Confirmed Invasive Pulmonary Aspergillosis and COVID-19: the value of postmortem findings to support antemortem management.确诊侵袭性肺曲霉病和 COVID-19:尸检结果对支持生前治疗的价值。
Rev Soc Bras Med Trop. 2020;53:e20200401. doi: 10.1590/0037-8682-0401-2020. Epub 2020 Jul 3.
5
Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion.重症监护病房患者流感相关肺曲霉病综述及病例定义建议:专家意见
Intensive Care Med. 2020 Aug;46(8):1524-1535. doi: 10.1007/s00134-020-06091-6. Epub 2020 Jun 22.
6
Invasive pulmonary aspergillosis in severe coronavirus disease 2019 pneumonia.2019年冠状病毒病重症肺炎中的侵袭性肺曲霉病
Clin Microbiol Infect. 2020 Oct;26(10):1428-1429. doi: 10.1016/j.cmi.2020.05.032. Epub 2020 Jun 2.
7
COVID-19-associated pulmonary aspergillosis (CAPA) in patients admitted with severe COVID-19 pneumonia: An observational study from Pakistan.重症新型冠状病毒肺炎(COVID-19)患者中与COVID-19相关的肺曲霉病(CAPA):一项来自巴基斯坦的观察性研究。
Mycoses. 2020 Aug;63(8):766-770. doi: 10.1111/myc.13135. Epub 2020 Jul 18.
8
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.COVID-19 住院成人患者使用伊马替尼的安全性和疗效:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9.
9
Putative invasive pulmonary aspergillosis in critically ill patients with COVID-19: An observational study from New York City.COVID-19 重症患者疑似侵袭性肺曲霉病:来自纽约市的观察性研究。
Mycoses. 2020 Dec;63(12):1368-1372. doi: 10.1111/myc.13185. Epub 2020 Oct 1.
10
COVID-19-Associated Invasive Aspergillosis: Data from the UK National Mycology Reference Laboratory.COVID-19 相关侵袭性曲霉病:来自英国国家真菌学参考实验室的数据。
J Clin Microbiol. 2020 Dec 17;59(1). doi: 10.1128/JCM.02136-20.

引用本文的文献

1
A systematic review on impact of SARS-CoV-2 infection.关于 SARS-CoV-2 感染影响的系统评价。
Microbiol Res. 2023 Jun;271:127364. doi: 10.1016/j.micres.2023.127364. Epub 2023 Mar 15.
2
COVID-19-Associated Pulmonary Aspergillosis (CAPA).新型冠状病毒肺炎相关肺曲霉病(CAPA)
J Intensive Med. 2021 Aug 7;1(2):71-80. doi: 10.1016/j.jointm.2021.07.001. eCollection 2021 Oct.
3
-SARS-CoV-2 Coinfection: What Is Known?- 严重急性呼吸综合征冠状病毒2型合并感染:已知情况有哪些?

本文引用的文献

1
Diagnosing COVID-19-associated pulmonary aspergillosis.诊断新型冠状病毒肺炎相关肺曲霉病
Lancet Microbe. 2020 Jun;1(2):e53-e55. doi: 10.1016/S2666-5247(20)30027-6. Epub 2020 May 10.
2
Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion.重症监护病房患者流感相关肺曲霉病综述及病例定义建议:专家意见
Intensive Care Med. 2020 Aug;46(8):1524-1535. doi: 10.1007/s00134-020-06091-6. Epub 2020 Jun 22.
3
Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19.
Pathogens. 2022 Oct 25;11(11):1227. doi: 10.3390/pathogens11111227.
4
Comparative risk assessment of COVID-19 associated mucormycosis and aspergillosis: A systematic review.新型冠状病毒肺炎相关毛霉菌病和曲霉病的比较风险评估:一项系统评价
Health Sci Rep. 2022 Aug 18;5(5):e789. doi: 10.1002/hsr2.789. eCollection 2022 Sep.
5
CT findings of COVID-19-associated pulmonary aspergillosis: a systematic review and individual patient data analysis.COVID-19 相关肺曲霉病的 CT 表现:系统评价和个体患者数据分析。
Clin Imaging. 2022 Oct;90:11-18. doi: 10.1016/j.clinimag.2022.07.003. Epub 2022 Jul 23.
6
Antifungal therapy in the management of fungal secondary infections in COVID-19 patients: A systematic review and meta-analysis.COVID-19 患者真菌感染的抗真菌治疗:系统评价和荟萃分析。
PLoS One. 2022 Jul 28;17(7):e0271795. doi: 10.1371/journal.pone.0271795. eCollection 2022.
7
Fungal Infection in Co-infected Patients With COVID-19: An Overview of Case Reports/Case Series and Systematic Review.新冠病毒合并感染患者的真菌感染:病例报告/病例系列概述与系统评价
Front Microbiol. 2022 Jul 6;13:888452. doi: 10.3389/fmicb.2022.888452. eCollection 2022.
8
Clinical and Imaging Features of COVID-19-Associated Pulmonary Aspergillosis.新型冠状病毒肺炎相关肺曲霉病的临床及影像学特征
Diagnostics (Basel). 2022 May 11;12(5):1201. doi: 10.3390/diagnostics12051201.
9
A post-COVID-19 posterior mediastinitis: Case report.新型冠状病毒肺炎后纵隔炎:病例报告
SAGE Open Med Case Rep. 2022 Feb 28;10:2050313X221081386. doi: 10.1177/2050313X221081386. eCollection 2022.
10
Incidence and Risk Factors of COVID-19-Associated Pulmonary Aspergillosis in Intensive Care Unit-A Monocentric Retrospective Observational Study.重症监护病房中新冠病毒相关肺曲霉病的发病率及危险因素——一项单中心回顾性观察研究
Pathogens. 2021 Oct 22;10(11):1370. doi: 10.3390/pathogens10111370.
新型冠状病毒肺炎(COVID-19)重症患者中疑似侵袭性肺曲霉病的患病率。
Lancet Respir Med. 2020 Jun;8(6):e48-e49. doi: 10.1016/S2213-2600(20)30237-X. Epub 2020 May 20.
4
Fatal Invasive Aspergillosis and Coronavirus Disease in an Immunocompetent Patient.免疫功能正常患者的侵袭性曲霉病和冠状病毒病致死。
Emerg Infect Dis. 2020 Jul;26(7):1636-1637. doi: 10.3201/eid2607.201603. Epub 2020 Jun 21.
5
COVID-19 associated pulmonary aspergillosis.COVID-19 相关肺曲霉病。
Mycoses. 2020 Jun;63(6):528-534. doi: 10.1111/myc.13096. Epub 2020 May 15.
6
Invasive fungal diseases during COVID-19: We should be prepared.2019冠状病毒病期间的侵袭性真菌病:我们应做好准备。
J Mycol Med. 2020 Jun;30(2):100971. doi: 10.1016/j.mycmed.2020.100971. Epub 2020 Apr 6.
7
Estimates of the severity of coronavirus disease 2019: a model-based analysis.新型冠状病毒疾病 2019 严重程度的估计:基于模型的分析。
Lancet Infect Dis. 2020 Jun;20(6):669-677. doi: 10.1016/S1473-3099(20)30243-7. Epub 2020 Mar 30.
8
On the use of corticosteroids for 2019-nCoV pneumonia.关于皮质类固醇在2019新型冠状病毒肺炎中的应用。
Lancet. 2020 Feb 29;395(10225):683-684. doi: 10.1016/S0140-6736(20)30361-5. Epub 2020 Feb 12.
9
Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study.中国武汉严重 COVID-19 患者的临床病程和结局:一项单中心、回顾性、观察性研究。
Lancet Respir Med. 2020 May;8(5):475-481. doi: 10.1016/S2213-2600(20)30079-5. Epub 2020 Feb 24.
10
Communicating the Risk of Death from Novel Coronavirus Disease (COVID-19).新型冠状病毒肺炎(COVID-19)死亡风险的传达
J Clin Med. 2020 Feb 21;9(2):580. doi: 10.3390/jcm9020580.